Archives
-
Nur77 Phase Separation and Bcl-2 Condensates
2026-10-03
The reference study identifies XS561 as a Nur77 ligand that promotes Nur77 movement to mitochondria and activates apoptosis in breast cancer models. Its central innovation is linking Nur77 phase separation and Nur77/Bcl-2 condensate formation with the conversion of Bcl-2 from a survival factor into a pro-apoptotic mediator.
-
CA2 Perineuronal Nets and Social Memory in Alzheimer’s
2026-10-02
A 2025 study identifies degradation of hippocampal CA2 perineuronal nets as a causal link between Alzheimer’s disease pathology and impaired social cognition memory in 5XFAD mice. By combining structural, transcriptomic, behavioral, genetic, enzymatic, and pharmacological approaches, the authors show that limiting MMP-dependent proteolysis preserves CA2 nets and delays social memory loss.
-
Phebestin and Bestatin in Antiplasmodial Research
2026-10-01
The reference study identifies Phebestin, a Bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial compound active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Its combination of stage-specific assays, parasite morphology, computational target analysis, and mouse efficacy studies provides a useful framework for evaluating aminopeptidase-directed antimalarial candidates while highlighting the limits of extrapolating from Bestatin-related chemistry.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-10-01
Zhao and colleagues describe a standardized whole-blood assay for measuring how metabolic interventions reshape cytokine responses to pattern-recognition receptor and microbial stimuli. The protocol preserves the complexity of human blood while introducing structured controls for sample handling, stimulation, metabolic modulation, and cytokine quantification, improving comparability across immunometabolism studies.
-
Metoprolol Tartrate for Reliable β1 Assays
2026-09-30
Learn how Metoprolol Tartrate (SKU B1339) can improve interpretation of viability, proliferation, and receptor-signaling assays through β1-selective experimental design. This scenario-based guide connects product specifications with recent hematopoietic regeneration evidence and practical workflow controls.
-
TCAIM–OGDH Control of Mitochondrial Metabolism
2026-09-30
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work reveals that mitochondrial proteostasis can directly tune TCA-cycle enzyme abundance, OGDH complex activity, and carbohydrate catabolism in cells and mice.
-
CHIR-99021 (CT99021) HCl Protocol Guide
2026-09-29
CHIR-99021 (CT99021) HCl provides a small-molecule way to perturb GSK-3α/β in stem-cell, signaling, metabolic, and T-cell workflows, with product-dossier potency and solubility information to guide setup. It should be used as a model-specific experimental modulator—not a universal cellular dose, validated clinical treatment, or substitute for matched literature evidence.
-
TCAIM, OGDH, and Mitochondrial Metabolism
2026-09-29
Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1, rather than supporting conventional protein folding. The study links this proteostasis mechanism to reduced OGDH complex activity and altered carbohydrate metabolism in cultured cells and murine models.
-
Axitinib (AG 013736): VEGFR Research Guide
2026-09-28
Axitinib, also called AG 013736, is an orally bioavailable and selective VEGFR1/2/3 tyrosine kinase inhibitor for angiogenesis and cancer biology research. Its subnanomolar receptor activity, pathway-level effects, cellular endothelial assay results, and xenograft benchmark support mechanistically resolved preclinical workflows rather than direct clinical-dose inference.
-
Tiamulin: Workflows for Infection and Metabolism Studies
2026-09-28
Tiamulin supports veterinary-pathogen assays and studies of drug metabolism, but species-specific biotransformation makes sample choice and analytical design critical. This guide translates its ribosomal mechanism and a multi-species metabolite study into practical workflows, controls, and troubleshooting steps.
-
CTOP for Causal Tests of Opioid Pain Circuits
2026-09-27
CTOP is a μ-opioid receptor antagonist that can help researchers test whether opioid receptor activity is necessary for a pain-circuit effect. This article connects the 2024 brain-to-spinal circuit findings to careful antagonist-experiment design, emphasizing localization, interpretation, and the limits of pharmacological inference.
-
ATP Solution as an Upstream Control in p21 mRNA Studies
2026-09-26
Learn how ATP Solution quality and handling can support reliable upstream RNA production and functional assays in p21 mRNA–LNP research. This perspective connects reagent control to the interpretation of localized bladder cancer studies without implying that ATP itself is a therapeutic agent.
-
LNP Surface Charge Meets V-ATPase Activity
2026-09-25
A 2026 study proposes that functional nucleic acid delivery depends on an interaction between LNP surface charge and target-cell V-ATPase activity, not nanoparticle properties alone. Its cell and animal findings suggest that the endo/lysosomal state of target tissues may help explain charge-associated delivery patterns, while leaving important formulation and mechanistic questions open.
-
AAL-993 and the Translational Logic of Angiogenesis
2026-09-25
A mechanistic and strategic guide to using AAL-993 as a VEGF receptor inhibitor in preclinical tumor angiogenesis research. The article distinguishes what the compound’s reported pharmacology supports from what remains untested, including the limits of drawing connections between glioma pathway studies and VEGFR inhibition.
-
Pexidartinib: Designing Better TAM Assays
2026-09-24
Pexidartinib (PLX3397) offers a way to perturb CSF1R signaling, but interpreting macrophage responses requires more than counting cells. This article connects its research use to a distinct SPP1-focused study and outlines assay choices that separate receptor inhibition from changes in tumor-associated myeloid-cell state.